Below are the most recent publications written about "Diabetic Nephropathies" by people in Profiles.
-
Kim YH, Saha MK, Hu Y, Kumar S, Poulton CJ, Hogan SL, Nachman P, Jennette JC, Nast CC, Mottl AK. Impact of Diabetic Lesions on Pathology, Treatment, and Outcomes of Glomerular Diseases. Kidney360. 2023 10 01; 4(10):1445-1453.
-
Ferkowicz MJ, Verma A, Barwinska D, Melo Ferreira R, Henderson JM, Kirkpatrick M, Silva PS, Steenkamp DW, Phillips CL, Waikar SS, Sutton TA. Molecular Signatures of Glomerular Neovascularization in a Patient with Diabetic Kidney Disease. Clin J Am Soc Nephrol. 2024 Feb 01; 19(2):266-275.
-
Buckley LF, Schmidt IM, Verma A, Palsson R, Adam D, Shah AM, Srivastava A, Waikar SS. Associations Between Kidney Histopathologic Lesions and Incident Cardiovascular Disease in Adults With Chronic Kidney Disease. JAMA Cardiol. 2023 04 01; 8(4):357-365.
-
Liu G, Li Y, Pan A, Hu Y, Chen S, Qian F, Rimm EB, Manson JE, Stampfer MJ, Giatsidis G, Sun Q. Adherence to a Healthy Lifestyle in Association With Microvascular Complications Among Adults With Type 2 Diabetes. JAMA Netw Open. 2023 01 03; 6(1):e2252239.
-
Braden GL, Landry DL. The Next Frontier: Biomarkers and Artificial Intelligence Predicting Cardiorenal Outcomes in Diabetic Kidney Disease. Kidney360. 2022 09 29; 3(9):1480-1483.
-
Cristancho C, Hemond CC. Serum Albumin Modifies the Effect of Peripheral Blood Monocytes on Severity of Diabetic Nephropathy in an Adult Population. Can J Diabetes. 2022 Feb; 46(1):69-74.
-
Patel AB, Mistry K, Verma A. DAPA-CKD: Significant Victory for CKD with or without Diabetes. Trends Endocrinol Metab. 2021 06; 32(6):335-337.
-
Verma A, Patel AB. Finerenone: A Non-steroidal Mineralocorticoid Receptor Blocker for Diabetic Kidney Disease. Trends Endocrinol Metab. 2021 05; 32(5):261-263.
-
Verma A, Patel AB, Upadhyay A, Waikar SS. CREDENCE: Significant Victory for Diabetic Kidney Disease. Trends Endocrinol Metab. 2020 06; 31(6):391-393.
-
Hanrahan JP, Seferovic JP, Wakefield JD, Wilson PJ, Chickering JG, Jung J, Carlson KE, Zimmer DP, Frelinger AL, Michelson AD, Morrow L, Hall M, Currie MG, Milne GT, Profy AT. An exploratory, randomised, placebo-controlled, 14?day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension. Diabetologia. 2020 04; 63(4):733-743.